Active, Not Recruiting
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
NCT04302324
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Weill Cornell Medicine - Multiple Myeloma Center New York, United States